Sign Out
Recommended Dosage: The recommended doses of RYBREVANT, based on baseline body weight, are provided in Table 2, and the dosing schedule is provided in Table 3. (See Tables 2 and 3.)
Click on icon to see table/diagram/image
Click on icon to see table/diagram/imageAdminister premedications before each RYBREVANT infusion as recommended [see Recommended Premedications as follows]. Administer diluted RYBREVANT intravenously according to the infusion rates in Table 7, with the initial dose as a split infusion on Week 1 on Day 1 and Day 2 [see Preparation and Administration as follows]. Administer RYBREVANT until disease progression or unacceptable toxicity.
Recommended Premedications: Prior to initial infusion of RYBREVANT (Week 1, Days 1 and 2), administer premedication as described in Table 4 to reduce the risk of infusion-related reactions: [see Infusion-Related Reactions under Precautions]. (See Table 4.)
Click on icon to see table/diagram/imageAdminister both antihistamine and antipyretic prior to all infusions. Glucocorticoid administration required for Week 1, Days 1 and 2 doses only and as necessary for subsequent infusions.
Dosage Modifications for Adverse Reactions: The recommended RYBREVANT dose reductions for adverse reactions (see Table 6) are listed in Table 5. (See Table 5.)
Click on icon to see table/diagram/imageThe recommended RYBREVANT dosage modifications for adverse reactions are provided in Table 6. (See Table 6.)
Click on icon to see table/diagram/imagePreparation: Dilute and prepare RYBREVANT for intravenous infusion before administration.
Check that the RYBREVANT solution is colorless to pale yellow. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if discoloration or visible particles are present.
Determine the dose required (either 1050 mg or 1400 mg) and number of RYBREVANT vials needed based on patient's baseline weight [see Recommended Dosage as previously mentioned]. Each vial of RYBREVANT contains 350 mg of amivantamab-vmjw.
Withdraw and then discard a volume of either 5% dextrose solution or 0.9% sodium chloride solution from the 250 mL infusion bag equal to the volume of RYBREVANT to be added (i.e., discard 7 mL diluent from the infusion bag for each RYBREVANT vial). Only use infusion bags made of polyvinylchloride (PVC), polypropylene (PP), polyethylene (PE), or polyolefin blend (PP+PE).
Withdraw 7 mL of RYBREVANT from each vial and add it to the infusion bag. The final volume in the infusion bag should be 250 mL. Discard any unused portion left in the vial.
Gently invert the bag to mix the solution. Do not shake.
Diluted solutions should be administered within 10 hours (including infusion time) at room temperature 59°F to 77°F (15°C to 25°C).
Administration: Administer the diluted solution [see Preparation as previously mentioned] by intravenous infusion using an infusion set fitted with a flow regulator and with an in-line, sterile, non-pyrogenic, low protein-binding polyethersulfone (PES) filter (pore size 0.2 micrometer) primed with diluent only. Administration sets must be made of either polyurethane (PU), polybutadiene (PBD), PVC, PP, or PE.
Do not infuse RYBREVANT concomitantly in the same intravenous line with other agents.
Administer RYBREVANT via a peripheral line on Week 1 and Week 2 given the high incidence of infusion-related reactions during initial treatment [see Infusion-Related Reactions under Precautions]. RYBREVANT may be administered via central line for subsequent weeks. For the initial infusion, prepare RYBREVANT as close to administration time as possible to allow for the possibility of extended infusion time in the event of an infusion-related reaction.
Administer RYBREVANT infusion intravenously according to the infusion rates in Table 7. (See Table 7.)
Click on icon to see table/diagram/imagePediatric Use: The safety and efficacy of RYBREVANT have not been established in pediatric patients.
Geriatric Use: Of the 129 patients treated with RYBREVANT, 41% were 65 years of age or older, and 9% were 75 years of age or older. No clinically important differences in safety or efficacy were observed between patients who were ≥65 years of age and younger patients.
